ArticleThe American journal of pathology2016
Death Receptor 3 Promotes Chemokine-Directed Leukocyte Recruitment in Acute Resolving Inflammation and Is Essential for Pathological Development of Mesothelial Fibrosis in Chronic Disease.
Article in The American journal of pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Inflammatory bowel disease treatment: Mechanisms to clinical translation (Review).International journal of molecular medicine · 2026Review
- Unravelling the TL1A-DR3 axis in Hidradenitis suppurativa.Frontiers in immunology · 2026Review
- Intestinal Fibrosis in Crohn's Disease: Pathophysiology, Diagnosis, and New Therapeutic Targets.Journal of clinical medicine · 2025Review
- Clinical Model Based on DR3 Promoter Methylation for Predicting Short-Term Mortality in Patients with Acute-on-Chronic Hepatitis B Liver Failure.International journal of general medicine · 2025Article
- A nomogram model based on tumor necrosis factor-like ligand 1A(TL1A) and death receptor-3(DR3) promoter methylation for predicting 90-day prognosis in patients with HBV-associated acute-on-chronic liver failure.Frontiers in molecular biosciences · 2025Article
- TL1A and IL-18 synergy promotes GM-CSF-dependent thymic granulopoiesis in mice.Cellular & molecular immunology · 2024Article
- Matrine improves the hepatic microenvironment and reverses epithelial-mesenchymal transition in hepatocellular carcinoma by inhibiting the Wnt-1/β-catenin signaling pathway.American journal of translational research · 2023Article
- Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.Inflammatory bowel diseases · 2022Article
- Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review).Experimental and therapeutic medicine · 2021Review
- TL1A Promotes Lung Tissue Fibrosis and Airway Remodeling.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Matrine prevents the early development of hepatocellular carcinoma like lesions in rat liver.Experimental and therapeutic medicine · 2019Article
- Whole-exome sequencing indicatesExperimental biology and medicine (Maywood, N.J.) · 2019Article
- Death Receptor 3 regulates distinct pathological attributes of acute versus chronic murine allergic lung inflammation.Cellular immunology · 2017Article
- Pathogenic Mechanisms and Host Interactions inFrontiers in microbiology · 2017Review
- Tumor necrosis and infiltrating macrophages predict survival after curative resection for cholangiocarcinoma.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Death receptor 3 (DR3; TNFRSF25) and its tumor necrosis factor-like ligand TL1A (TNFSF15) control several processes in inflammatory diseases through the expansion of effector T cells and the induction of proinflammatory cytokines from myeloid and innate lymphoid cells. Using wild-type (DR3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.